Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Fineline Cube Jul 3, 2026
Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Fineline Cube Jul 3, 2026
Company Drug

Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity

Fineline Cube May 12, 2025

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...

Company Drug

RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis

Fineline Cube May 12, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...

Company Drug

NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Deals

XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million

Fineline Cube May 12, 2025

Shenzhen-based XtalPi Holdings Limited (HKG: 2228) announced plans to acquire a 90% stake in Re...

Company Medical Device

Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters

Fineline Cube May 12, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Drug

Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval

Fineline Cube May 9, 2025

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...

Company Drug

J&J’s Tremfya Approved for Ulcerative Colitis in China

Fineline Cube May 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...

Policy / Regulatory

China’s CDE Reveals 93rd Batch of Reference Preparations for GQCE

Fineline Cube May 9, 2025

China’s Center for Drug Evaluation (CDE) has released the 93rd batch of reference preparations for...

Policy / Regulatory

NHC Issues Guidelines for Geriatric Medicine Departments Construction and Management

Fineline Cube May 9, 2025

The National Health Commission (NHC) this week released the “Guidelines for the Construction and Management...

Company

Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales

Fineline Cube May 9, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April...

Company

Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress

Fineline Cube May 9, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report...

Company Drug

Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials

Fineline Cube May 9, 2025

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...

Company Deals Hospital

Prudential Hong Kong Collaborates with Foshan Fosun Chancheng Hospital for Direct Payment Services

Fineline Cube May 9, 2025

Prudential Hong Kong Limited, a subsidiary of UK-based Prudential plc, has entered into a strategic...

Company Deals

Sanyou Medical Partners with CGBio to Launch Regenerative Medicine Joint Venture

Fineline Cube May 9, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced plans to establish a joint venture...

Company Drug

Hengrui Pharma Files for New Dalpiciclib Indication in Early Breast Cancer

Fineline Cube May 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that a new indication approval filing...

Company Deals

Gilead Sciences Announces $11 Billion Investment in US Expansion

Fineline Cube May 9, 2025

US-based major Gilead Sciences Inc. (NASDAQ: GILD) announced an additional investment of USD 11 billion...

Company Drug

Humanwell Healthcare Gains NMPA Approval for Giapreza Generic in Shock Therapy

Fineline Cube May 9, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clinical trial...

Company Drug

Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial

Fineline Cube May 9, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from...

Company Deals

Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area

Fineline Cube May 9, 2025

US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...

Company Deals

Insilico Medicine Files for IPO to Leverage AI in Drug Discovery

Fineline Cube May 9, 2025

China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...

Posts pagination

1 … 189 190 191 … 690

Recent updates

  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
  • Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors
  • Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older
  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Company Drug

Bio-sincerity Secures NMPA Clinical Trial Approval for BIOS0629-109, Novel XPO1 Inhibitor for Advanced Malignant Tumors

Company Drug

Novartis Secures EU Approval for Itvisma, First Gene Replacement Therapy for Broad SMA Population Including Patients Two Years and Older

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.